Needham analyst Michael Matson maintained a Buy rating on Haemonetics today and set a price target of $78.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors including Haemonetics’ recent financial performance and future outlook. The company exceeded expectations in both revenue and earnings per share for the second quarter of fiscal year 2026, prompting an upward revision of its financial guidance. Despite a slight decline in organic growth, Haemonetics showed strong performance in plasma sales excluding CSL, which increased significantly.
Additionally, the company’s margins have improved, with a notable increase in both gross and operating margins compared to the previous year. These financial improvements, along with the company’s strategic adjustments and conservative guidance for hospital operations, have led to an increased price target, reflecting confidence in Haemonetics’ potential for continued growth.
In another report released today, BTIG also reiterated a Buy rating on the stock with a $88.00 price target.